Familial Hypercholesterolaemia (FH) is a monogenic disorder characterised by high LDL-C concentrations and increased cardiovascular risk. However, in clinically defined FH cohorts worldwide, an FH-causing variant is only found in 40-50% of the cases. The aim of this work was to characterise the genetic cause of the FH phenotype in Portuguese clinical FH patients. Methods and Results Between 1999 and 2017, 731 index patients (311 children and 420 adults) who met the Simon Broome diagnostic criteria had been referred to our laboratory. LDLR, APOB, PCSK9, APOE, LIPA, LDLRAP1, ABCG5/8 genes were analysed by PCR amplification and Sanger sequencing. The 6-SNP LDL-C genetic risk score (GRS) for polygenic hypercholesterolaemia was validated in the ...
Familial hypercholesterolemia (FH) is an autosomal dominant genetic disorder caused, in the majority...
Familial Hypercholesterolaemia (FH) is an autosomal dominant disorder with a frequency of 1 in 250 t...
Background Evidence suggests that LPA risk genotypes are a possible contributor to the clinical diag...
Familial hypercholesterolaemia (FH) is a monogenic autosomal condition where patients present very ...
Familial Hypercholesterolaemia (FH) is a monogenic lipid disorder caused by mutations in LDLR, APOB,...
Familial hypercholesterolemia (FH) is an autossomal dominant disorder associated with high levels of...
INTRODUCTION : Familial hypercholesterolemia (FH) is a common autosomal dominant disorder of lipid m...
amilial hypercholesterolaemia (FH) is a monogenic disorder of low-density lipoprotein (LDL) metaboli...
Familial Hypercholesterolemia (FH) is a genetic disorder characterized by high levels of LDLc in pla...
Familial hypercholesterolemia (FH) is a common autosomal dominant disorder of lipid metabolism (1:50...
Familial hypercholesterolaemia (FH) is characterised clinically by an increased level of circulating...
Introduction: Familial Hypercholesterolemia (FH) is a common autosomal genetic disorder (1/250-1/50...
In the early 1980s, the Nobel Prize winning cellular and molecular work of Mike Brown and Joe Goldst...
Familial Hypercholesterolemia (FH) is a genetic autosomal dominant disorder characterized clinically...
In the early 1980s, the Nobel Prize winning cellular and molecular work of Mike Brown and Joe Goldst...
Familial hypercholesterolemia (FH) is an autosomal dominant genetic disorder caused, in the majority...
Familial Hypercholesterolaemia (FH) is an autosomal dominant disorder with a frequency of 1 in 250 t...
Background Evidence suggests that LPA risk genotypes are a possible contributor to the clinical diag...
Familial hypercholesterolaemia (FH) is a monogenic autosomal condition where patients present very ...
Familial Hypercholesterolaemia (FH) is a monogenic lipid disorder caused by mutations in LDLR, APOB,...
Familial hypercholesterolemia (FH) is an autossomal dominant disorder associated with high levels of...
INTRODUCTION : Familial hypercholesterolemia (FH) is a common autosomal dominant disorder of lipid m...
amilial hypercholesterolaemia (FH) is a monogenic disorder of low-density lipoprotein (LDL) metaboli...
Familial Hypercholesterolemia (FH) is a genetic disorder characterized by high levels of LDLc in pla...
Familial hypercholesterolemia (FH) is a common autosomal dominant disorder of lipid metabolism (1:50...
Familial hypercholesterolaemia (FH) is characterised clinically by an increased level of circulating...
Introduction: Familial Hypercholesterolemia (FH) is a common autosomal genetic disorder (1/250-1/50...
In the early 1980s, the Nobel Prize winning cellular and molecular work of Mike Brown and Joe Goldst...
Familial Hypercholesterolemia (FH) is a genetic autosomal dominant disorder characterized clinically...
In the early 1980s, the Nobel Prize winning cellular and molecular work of Mike Brown and Joe Goldst...
Familial hypercholesterolemia (FH) is an autosomal dominant genetic disorder caused, in the majority...
Familial Hypercholesterolaemia (FH) is an autosomal dominant disorder with a frequency of 1 in 250 t...
Background Evidence suggests that LPA risk genotypes are a possible contributor to the clinical diag...